Beck Depression Inventory-II (BDI-II)

The BDI-II is copyrighted by Pearson Assessments. Purchase of the instrument kit (test booklets, scoring materials) is required for authorized use. Typical cost is approximately 50–100 USD for a starter kit. Online scoring platforms (e.g., Pearson's Q-local) charge per administration. Researchers and clinicians must have explicit permission to use and must cite the instrument appropriately.

PHQ-9 (9 items, 0–27 range) is a brief screening tool suitable for primary care; BDI-II (21 items, 0–63 range) provides comprehensive assessment for detailed symptom profiling and treatment monitoring. BDI-II uses multiple response descriptors per item, offering finer severity discrimination. PHQ-II is free and in public domain; BDI-II requires purchase. Choose BDI-II for detailed clinical assessment, PHQ-9 for efficient screening.

No. The BDI-II measures symptom severity, not diagnosis. A clinician must conduct a diagnostic interview to confirm major depressive disorder, rule out bipolar disorder or adjustment disorder, and assess suicidality and functional impairment. A high BDI-II score signals the presence of depressive symptoms warranting clinical evaluation but does not confirm a diagnosis.

Frequency depends on treatment intensity. In weekly psychotherapy, administer every 1–4 weeks to track session-to-session progress. In medication management, administer at baseline, weeks 4–6, 8–12, and at outcome (monthly or less frequent). In intensive inpatient settings, every 3–7 days is reasonable. More frequent administration (e.g., daily) risks respondent fatigue without added clinical benefit.

Item-level examination is clinically valuable. High hopelessness (even with overall moderate score) indicates high suicide risk and warrants direct safety assessment and close monitoring. Conversely, anhedonia-dominant profiles (loss of interest/pleasure) suggest different treatment targets than fatigue-dominant profiles. Always review item content, not just totals.